Table 2.

Estimates for hazard ratios for progression-free survival and overall survival in the pembrolizumab group.

Factors	PFS		OS
	Multivariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age (≥60 vs <60)	7.32 (1.90~28.21)	0.004
PD-L1 status (≥1% vs <1%)	0.26 (0.10~0.70)	0.007	0.16 (0.04~0.68)	0.013
APC (≥220 vs <220)	5.25 (1.51~18.25)	0.009
PLR (≥120 vs <120)	10.72 (1.67~68.81)	0.012

HR, hazard ratios; CI, confidence interval; PFS, progression-free survival; OS, overall survival; PD-L1 TPS, programmed death-1 tumor proportion score; APC, absolute platelet count; PLR, platelet-to-lymphocyte ratio.